CDK4 and cancer: Hence, activation of CDK2, independent of CDK4/6 activity, may limit the potency of CDK4/6is in cancers, and identification of signalling required for CDK2 activation may yield information that predicts CDK4/6 inhibitor response, or be exploited to extend their efficacy in cancer therapy.